ST3GAL2 Antibody

What is ST3GAL2 and why is it significant in cancer research?

ST3GAL2 (ST3 beta-Galactoside alpha-2,3-Sialyltransferase 2) is an enzyme that catalyzes the transfer of sialic acid to glycoproteins and glycolipids, with a preference for the latter, particularly gangliosides GD1a and GT1b . Its significance in cancer research stems from its consistent overexpression across various cancer types. RNA-Seq database analysis revealed that the ST3GAL2 gene is significantly overexpressed at all stages of colorectal cancer (CRC) . The enzyme is responsible for the synthesis of Stage Specific Embryonic Antigen-4 (SSEA-4), a glycosphingolipid exclusively produced by ST3GAL2 that serves as a biomarker for several cancers including hepatocellular carcinoma, prostate tumors, and breast cancer .

ST3GAL2 shows distinct expression patterns between normal and cancerous tissues:

• In normal tissues: ST3GAL2 maintains physiological sialylation of gangliosides, particularly in brain tissue where it mediates α2,3 sialylation of gangliosides .

• In cancerous tissues: ST3GAL2 is significantly overexpressed at all stages of colorectal cancer . Studies have shown that increased mRNA expression of ST3GAL2 is associated with advanced cancer stages and poor clinical outcomes .

The biological significance of this differential expression is demonstrated by knockdown studies where decreased ST3GAL2 expression leads to reduced tumor cell proliferation, migration, and invasiveness properties in vitro .

How should I design ST3GAL2 knockdown experiments to study its function in cancer cells?

Based on successful published methodologies , consider the following approach:

• Selection of appropriate cell line: Choose cell lines with confirmed ST3GAL2 overexpression. For colorectal cancer studies, HT29 (stage II-derived) has been successfully used .

• Knockdown strategy:

  • shRNA approach: Use a pool of 3 target-specific lentiviral vector plasmids encoding 19-25 nucleotides shRNA designed to knock down ST3GAL2 .

  • Create both polyclonal populations and clonal selections to ensure effects aren't clone-dependent .

• Validation of knockdown efficiency:

  • qRT-PCR: Measure ST3GAL2 mRNA levels using specific probes (e.g., HS00199480-m1) .

  • Western blotting: Confirm protein reduction using anti-ST3GAL2 antibodies.

  • Functional validation: Measure the loss of SSEA-4 epitope using immunofluorescence or flow cytometry .

• Functional assays:

  • Proliferation: Cell counting or MTT/WST-1 assays over multiple timepoints.

  • Migration: Wound healing or transwell migration assays.

  • Invasion: Matrigel-coated transwell assays.

  • Cell cycle analysis: Flow cytometry with propidium iodide staining.

  • Apoptosis assessment: Annexin V/PI staining.

• In vivo validation: Consider xenograft models in immunocompromised mice to assess tumor growth characteristics .

What are the most effective methods for detecting ST3GAL2 protein expression in tissue samples?

Multiple complementary approaches can be used:

• Western blotting:

  • Sample preparation: Use RIPA buffer with protease inhibitors for tissue homogenization.

  • Detection: Primary antibodies can detect ST3GAL2 at approximately 40 kDa under reducing conditions .

  • Controls: Human heart tissue expresses detectable levels of ST3GAL2 and can serve as a positive control .

• Immunohistochemistry (IHC):

  • Fixation: Formalin-fixed paraffin-embedded (FFPE) sections are suitable.

  • Antigen retrieval: Heat-induced epitope retrieval in citrate buffer (pH 6.0).

  • Detection systems: Polymer-based detection systems provide better signal-to-noise ratio.

  • Controls: Include both positive tissue controls and negative controls (primary antibody omission).

• Mass spectrometry:

  • For more precise quantification and characterization of ST3GAL2 expression and its associated sialylated glycans .

How do I optimize antibody dilutions for Western blotting and immunohistochemistry?

For optimal results, consider this systematic approach:

Western Blotting Optimization:

• Start with manufacturer's recommended dilution (typically 0.5-1 μg/mL) .

• Perform titration experiments using 2-fold serial dilutions.

• For polyclonal antibodies targeting ST3GAL2, start with 1:500-1:1000 dilutions.

• Optimize blocking conditions to reduce background (5% non-fat milk or BSA in TBST).

• For challenging tissues, consider using specialized immunoblot buffer systems like Immunoblot Buffer Group 1 .

Immunohistochemistry Optimization:

• Begin with dilutions of 1:100-1:200 for FFPE sections.

• Optimize antigen retrieval conditions (citrate vs. EDTA buffers, pH variations).

• Test different incubation times (1 hour at room temperature vs. overnight at 4°C).

• Include appropriate controls including isotype controls (matching IgG2a for mouse monoclonal antibodies) .

How can ST3GAL2 antibodies be used to investigate the relationship between sialylation and tumor immune evasion?

Recent research indicates ST3GAL2-mediated sialylation may contribute to tumor immune evasion mechanisms :

• Siglec receptor engagement:

  • ST3GAL2 generates ligands for immunoregulatory Siglec-7 and Siglec-9 receptors .

  • Co-immunoprecipitation using ST3GAL2 antibodies can help identify interactions between sialylated products and Siglec receptors.

  • Flow cytometry with dual labeling (anti-ST3GAL2 and anti-Siglec antibodies) can quantify these interactions.

• Functional immune assays:

  • Co-culture experiments with immune cells (NK cells, T cells) and ST3GAL2-expressing or knockdown tumor cells.

  • Measure immune cell activation markers, cytokine production, and cytotoxicity.

  • Antibody blocking experiments to disrupt ST3GAL2-mediated sialylation.

• In vivo immune contexture analysis:

  • Immunohistochemical co-staining of ST3GAL2 with immune cell markers in tumor samples.

  • Correlation of ST3GAL2 expression with immune infiltration patterns.

  • Analysis of checkpoint molecule expression in relation to ST3GAL2 levels.

What strategies can be employed to validate ST3GAL2 antibody specificity?

Ensuring antibody specificity is critical for reliable research outcomes:

• Genetic validation:

  • Use ST3GAL2 knockout or knockdown models as negative controls .

  • Genetic rescue experiments by reintroducing ST3GAL2 to knockout systems.

  • Test antibodies on cell lines with defined ST3GAL2 expression levels.

• Peptide competition assays:

  • Pre-incubate antibody with excess immunizing peptide (e.g., AA 28-127 for ABIN562877) .

  • Compare staining patterns with and without peptide blocking.

• Cross-reactivity assessment:

  • Test on tissues from ST3GAL2 knockout mice .

  • Evaluate reactivity in tissues expressing other ST3GAL family members to confirm specificity.

• Functional validation:

  • Correlate antibody staining with SSEA-4 expression, which is exclusively produced by ST3GAL2 .

  • Perform enzymatic activity assays in parallel with antibody detection.

How can I distinguish between ST3GAL2 and other sialyltransferases in my experiments?

Differentiating ST3GAL2 from related sialyltransferases requires multiple approaches:

• Antibody selection:

  • Choose antibodies raised against unique regions of ST3GAL2 that do not share homology with other ST3GAL family members.

  • The N-terminal region (AA 28-127) shows less conservation across the family .

• Expression pattern analysis:

  • ST3GAL2 preferentially sialylates glycolipids, while ST3GAL1 primarily targets O-glycoproteins .

  • ST3GAL2 uniquely produces SSEA-4, which can serve as a functional readout .

• Substrate specificity assays:

  • Use purified substrates specific to each enzyme.

  • For ST3GAL2, its preferred substrates are ganglio-series glycolipids GM1b and GD1a .

• qPCR with highly specific primers:

  • Design primers that target unique regions of each sialyltransferase gene.

  • Validate primer specificity using overexpression systems.

Why might I observe variable ST3GAL2 staining patterns in different cancer types, and how can I address this?

Variability in ST3GAL2 staining can result from multiple factors:

• Expression level differences:

  • ST3GAL2 is overexpressed to varying degrees across cancer types.

  • In colorectal cancer, expression increases across all stages , while other cancers may show stage-specific patterns.

  • Solution: Include positive controls with known expression levels for each experiment.

• Post-translational modifications:

  • The 40 kDa protein may display different migration patterns due to glycosylation states.

  • Solution: Consider using deglycosylation enzymes before Western blotting.

• Cellular localization differences:

  • ST3GAL2 primarily localizes to the Golgi apparatus but may show altered distribution in cancer cells.

  • Solution: Use subcellular fractionation and co-staining with Golgi markers.

• Fixation and processing artifacts:

  • Antibody epitopes may be differentially affected by fixation protocols.

  • Solution: Test multiple fixation conditions and antigen retrieval methods.

What are the best approaches for studying the relationship between ST3GAL2 and its product SSEA-4 in cancer progression?

A multi-faceted approach is recommended:

• Co-expression analysis:

  • Dual immunostaining for ST3GAL2 and SSEA-4 in tissue sections.

  • Flow cytometry for simultaneous detection in cell populations.

  • Correlation analysis between ST3GAL2 mRNA/protein levels and SSEA-4 expression.

• Functional modulation:

  • ST3GAL2 knockdown should reduce SSEA-4 levels, confirming their relationship .

  • Overexpression of ST3GAL2 should increase SSEA-4 production.

  • Enzymatic inhibition studies to directly link enzyme activity to SSEA-4 levels.

• Clinical correlation studies:

  • Analyze patient samples for both markers and correlate with clinical outcomes.

  • Stage-specific expression patterns may provide insights into progression mechanisms.

• Mechanistic studies:

  • Investigate how SSEA-4 mediates the effects of ST3GAL2 on cancer cell behavior.

  • Assess receptor interactions and downstream signaling pathways activated by SSEA-4.

How can I interpret contradictory results between ST3GAL2 antibody staining and functional outcomes in my research?

When faced with contradictory results:

• Antibody validation reassessment:

  • Confirm antibody specificity using multiple approaches (western blot, IHC, knockout controls).

  • Consider testing multiple antibodies targeting different epitopes of ST3GAL2.

• Context-dependent effects:

  • ST3GAL2 functions may vary by cellular context. For instance, its role in prostate cancer appears inversely correlated with androgen receptor signaling .

  • Test hypotheses in multiple cell lines representing different cancer subtypes or stages.

• Substrate availability:

  • The functional impact of ST3GAL2 depends on the availability of appropriate acceptor substrates.

  • Consider analyzing the expression of glycolipid synthesis enzymes in your model system.

• Compensatory mechanisms:

  • Other sialyltransferases may compensate for ST3GAL2 alterations.

  • Analyze the complete sialyltransferase expression profile in your system.

  • In mouse brain, ST3Gal3 can partially compensate for loss of ST3Gal2 function .

What emerging applications of ST3GAL2 antibodies show promise for cancer research and diagnostics?

Several innovative applications are showing potential:

• Liquid biopsy development:

  • Detection of circulating ST3GAL2 or its products in patient serum.

  • Correlation with tumor burden and treatment response.

• Immunotherapy response prediction:

  • ST3GAL2-mediated sialylation may influence response to immunotherapies through Siglec receptor engagement .

  • Antibody-based assessment of sialylation status could predict responders.

• Therapeutic targeting strategies:

  • Developing antibody-drug conjugates targeting ST3GAL2 or SSEA-4 expressing cells.

  • Combinatorial approaches targeting sialylation alongside conventional therapies.

• Spatial transcriptomics integration:

  • Combining ST3GAL2 antibody staining with spatial transcriptomics to understand the tumor microenvironment.

  • Mapping sialylation patterns within heterogeneous tumor regions.

How can ST3GAL2 antibodies contribute to understanding the role of sialylation in cancer stem cell biology?

ST3GAL2 has emerging connections to cancer stem cell phenotypes:

• Cancer stem cell marker correlation:

  • SSEA-4 (produced by ST3GAL2) is expressed in breast cancer stem cells .

  • Co-staining experiments with ST3GAL2 antibodies and established stem cell markers.

• Functional stem cell assays:

  • Sphere formation capacity in relation to ST3GAL2 expression.

  • Limiting dilution assays to assess tumor-initiating potential.

  • Self-renewal and differentiation potential assessment.

• Chemoresistance mechanisms:

  • ST3GAL2-mediated sialylation has been associated with chemotherapy resistance in tumor cells .

  • Antibody-based sorting of ST3GAL2-high versus ST3GAL2-low populations for drug response testing.

• Therapeutic implications:

  • Developing strategies to target ST3GAL2-expressing cancer stem cells.

  • Monitoring treatment-induced changes in ST3GAL2 expression and sialylation patterns.